Eric Shaff is Former President and Chief Executive Officer of Seres Therapeutics, Inc. (MCRB). The company reported total compensation of $1,775,549 for fiscal year 2025.
| Salary | $408,333 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,338,870 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $28,346 |
| Total | $1,775,549 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Seres Therapeutics, Inc. filed April 27, 2026, accession 0001193125-26-182036.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Former President and Chief Executive Officer | $408,333 | $0 | $0 | $1,338,870 | $0 | $0 | $28,346 | $1,775,549 |
| FY2024 | Former President and Chief Executive Officer | $685,000 | $0 | $116,875 | $1,459,835 | $411,000 | $0 | $9,297 | $2,682,007 |
Totals as disclosed in each year's own compensation disclosure for Seres Therapeutics, Inc..
| Peer-group chief executive median | $2,646,831 |
|---|---|
| Difference from that median | $-871,281 |
| Percentile within the disclosed peer group | 1st |
| Peers with a disclosed figure | 9 |
Medians and percentiles are computed across the peer group Seres Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Eric Shaff this page | Former President and Chief Executive Officer | $1,775,549 |
| Thomas DesRosier | Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer | $1,136,023 |
| Marella Thorell | Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer | $1,113,396 |
| Teresa Young | Former Executive Vice President and Chief Commercial and Strategy Officer | $1,021,462 |
| Matthew Henn | President and Chief Scientific Officer | $1,014,347 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Seres Therapeutics, Inc. compensation brief.
Eric Shaff's compensation sits inside Seres Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.